Background. Since 2002, an epidemic of Clostridium difficile-associated-diarrhea (CDAD) associated with a high case-fatality rate has involved 130 hospitals in the province of Quebec, Canada. In 2003, a total of 55% of patients with CDAD at our hospital had received fluoroquinolones in the preceding 2 months. It has been suggested that massive use of proton pump inhibitors might have facilitated this epidemic.
portion of patients with CDAD who developed complications or who died р30 days after diagnosis was noted [4] . The predominant clone in Quebec is identical to a C. difficile strain with novel virulence factors found in the United States [1] . These virulence factors may be associated with more-severe disease and diarrhea, which in turn facilitate transmission of the pathogen within hospitals. Other factors that may have contributed to the rapid spread of this strain within Quebec include the substantial aging of the population of inpatients with numerous comorbidities; a lack of investment in hospital infrastructures, resulting in a shortage of private and semiprivate rooms (so that prevention of cross-transmission is more difficult); and, possibly, the introduction of alcohol-based hand washing. Finally, there appears to be a suboptimal response of this strain to metronidazole treatment, accompanied by frequent recurrences, which might have an impact on transmission dynamics [4, 5] .
In our hospital, the proportion of patients with CDAD who had received fluoroquinolones in the preceding 2 months increased from ∼10% in 1991-1996 to 55% in 2003 [4] , but it remained unclear to what extent this reflected changes in prescription practices. Furthermore, it has been suggested that the use of proton pump inhibitors (PPIs) might increase the risk of CDAD [6, 7] . In Canada, use of PPIs has increased exponentially in recent years: up to 50% of inpatients now receive PPIs at some point during their hospitalization [6] . If this association were causal, restriction of PPI use might be considered as a control measure for CDAD. To delineate the risk of CDAD associated with specific classes of antibiotics in the context of this epidemic, and to measure the effect of PPIs and other drugs that alter gastric acidity or gastrointestinal motility, we undertook a retrospective cohort study of patients hospitalized at the Centre Hospitalier Universitaire de Sherbrooke (Sherbrooke, Quebec), a 683-bed secondary and tertiary care hospital, during the peak of the C. difficile infection epidemic.
METHODS
We reviewed the records of all adult patients hospitalized at least once in the internal medicine, family medicine, or gastroenterology wards during the period of 1 January 2003 through 30 June 2004, as well as a random sample of 50% of patients hospitalized in the general surgery unit. For each individual, we reviewed all hospital admissions during that period, regardless of the admitting service. Hospitalizations for which the primary reason for admission was CDAD were excluded. Multiple hospitalizations for the same patient were considered to represent a single episode of care if the interval between the date of discharge from the hospital and the date of subsequent readmission was р60 days; in such cases, we tabulated the total number of days actually spent in the hospital as the sum of the durations of each hospitalization within that episode of care. Hospitalizations separated by 160 days were considered to be distinct events and were analyzed as 2 (or more) episodes of care. This approach was based on the maximum incubation period for CDAD, generally thought to be 60 days, and it aimed to consider multiple hospitalizations with short intervals as a single exposure, whereas hospitalizations separated by more than the maximum incubation period were analyzed as distinct exposures.
Sociodemographic, clinical, pharmaceutical, and laboratory data were extracted from the medical records (part of which are computerized, whereas medical and nursing notes remain handwritten). We collected data on level of care, use of antibiotics (during the hospital admissions, data were derived from the computerized medical records; for the 2 months prior to the episode of care, data were derived from medical notes) or other drugs (during hospital admissions), and procedures performed. To quantify the overall burden of comorbidities, we used the Charlson comorbidity index [8] ; because this index is based essentially on chronic diseases, we reviewed for each patient all discharge diagnoses during all hospital admissions up to the one that constituted the beginning of an episode of care. For patients who developed CDAD, data were collected from hospital admission up to the date of diagnosis of CDAD. We excluded colonoscopies during which a diagnosis of CDAD was made, because these procedures clearly did not antedate acquisition of C. difficile.
A patient was considered to have developed CDAD if (1) diarrhea developed during the episode of care or within 60 days after last discharge, and (2) either a stool specimen was found to have C. difficile toxin by the cytotoxicity assay, and/or colonoscopy revealed changes typical of pseudomembranous colitis, and/or histopathology supported that diagnosis [4] . Centre Hospitalier Universitaire de Sherbrooke is the only hospital in our region that performs C. difficile toxin assays (smaller hospitals forward their samples to our laboratory), so our measure of the outcome must have been fairly accurate. The probability of developing CDAD was measured using Kaplan-Meier analyses, in which day 0 corresponded to the date of first hospital admission for an episode of care, and data were censored when the patient died or 60 days after the date of the last hospital discharge within that episode of care, whichever came first. Crude and adjusted hazard ratios (AHRs) were measured using Cox regression. Variables significantly associated with CDAD in univariate analyses were then tested in Cox multivariate models, which were built up sequentially, starting with the variable most strongly associated with CDAD and continuing until no other variable reached significance or altered the AHR of variables already in the model. When the final model was reached, each variable was dropped in turn to assess its effect, different models being compared with the likelihood ratio test. We kept in the final model variables that were significant at the level. Interactions were sought between variables P p .05 other than antibiotics. The proportional hazards assumption was verified by comparing the Kaplan-Meier curve to the Cox predicted curve for a given variable, and by assessing the parallel nature of curves in log-log plots.
RESULTS
We obtained data on 7421 episodes of care corresponding to 5619 individuals; 4181 patients contributed to 1 episode of care, 1119 contributed to 2 episodes of care, 281 contributed to 3 episodes of care, and 38 patients contributed to у4 episodes of care. Of these 7421 episodes of care, 5091 corresponded to a single hospital admission, 1620 to 2 hospital admissions, and 710 to у3 hospital admissions. All analyses consider episodes Table 2 shows the factors associated with CDAD in univariate analyses. Older age, a high Charlson score, and a longer duration of hospitalization were strongly associated with CDAD. Among antibiotics, those with the highest univariate hazard ratios were fluoroquinolones and third-generation cephalosporins. Administration of PPIs, H 2 -blockers, laxatives, nonsteroidal antiinflammatory drugs, and corticosteroids was associated with CDAD, but less strongly so. Antacids and antimotility drugs were not associated with CDAD (data not shown). Many of these variables were confounded by each other, and the results of the multivariate Cox regression are also shown in table 2. The independent risk factors for CDAD were age, duration of hospitalization, a previous episode of CDAD independent of the current one, and having received fluoroquinolones, cephalosporins, macrolides, clindamycin, or intravenous b-lactam/ b-lactamase inhibitors. The adjusted hazard ratios were very similar for first-, second-, and third-generation cephalosporins. The Charlson score was strongly confounded by age and duration of hospital stay and was no longer significant after adjustment. The use of PPIs, laxatives, H 2 blockers, and tube feeding; having undergone surgery or endoscopy; and having received intensive care were confounded by the same factors and were not significantly associated with CDAD in multivariate analysis. No interaction was found between age, Charlson score, and duration of hospital stay.
To examine whether the risk of inducing CDAD was modulated by duration of antibiotic therapy, we compared (for those antibiotics independently associated with CDAD) the AHRs according to whether the drugs were given for 1-3 days, 4-6 days, or у7 days, adjusting for the other independent correlates of CDAD (table 3) . Although the 95% CIs often overlapped, it can be seen that for quinolones, first-generation cephalosporins, cefuroxime, clindamycin, and macrolides, a longer duration of use tended to enhance the risk of CDAD, whereas for cefoxitin, the risk was paradoxically higher when used as a single dose for perioperative prophylaxis.
To further characterize the risk associated with fluoroquinolones, we measured the drug-specific AHRs, which tended to be lower among the 368 patients given levofloxacin (AHR, 2.52; 95% CI, 1.68-3.79) than among the 1153 patients given ciprofloxacin (AHR, 3.74; 95% CI, 2.81-4.97) or in the 127 pa- ). n p 40
DISCUSSION
Among patients who receive antibiotics, several risk factors have been identified as potentially enhancing the risk of developing CDAD: advanced age, comorbidities, duration of hospitalization, stay in intensive care units, administration of antiulcer medications, use of laxatives, tube feeding, a poor immune response to toxin A, surgery, and nonsurgical gastrointestinal procedures [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Most of these risk factors are related to each other. Unfortunately, many previous studies with a limited sample size investigated a single risk factor without adjusting for confounders. Others used the case-control approach, which is prone to biases associated with the selection of control subjects [18, 19, 21] . Prior cohort studies that did not take survival into consideration had a biased estimate of the effect of variables themselves associated with death (such as age). They included !400 patients and !40 outcomes [12, [14] [15] [16] . Our study, conducted during an epidemic of nosocomial CDAD, included nearly 300 outcomes and had sufficient statistical power to adjust for numerous risk factors.
Duration of hospitalization, a strong risk factor for CDAD, must be viewed as a proxy for exposure to C. difficile spores in the hospital environment. Age was also a strong risk factor, but the presence of comorbidities (summarized by the Charlson score) was confounded by the former two (older, sicker patients were hospitalized for longer periods of time than were younger ones), with AHRs approaching the null value. Prior studies that identified comorbidities as a risk factor for CDAD did not adjust for both age and duration of hospital stay [10, 12, 15, 21] . Given the senescence of immunity [22] , it seems plausible that older individuals develop a less effective immune response against C. difficile toxins than do younger patients, but this remains to be confirmed [10, 11, 23] . Similarly, the finding that a prior episode of CDAD 13 months before the beginning of an episode of care was a risk factor for a new, independent episode may indicate that some individuals are intrinsically more at risk, perhaps because of a suboptimal immune response.
Several risk factors identified in prior studies were found to be unrelated to CDAD after adjustment for confounders. Use of PPIs was more common among older patients and among patients who were hospitalized for long periods of time and was not associated with CDAD in multivariate analysis. Previous reports implicating PPIs had little opportunity to adjust for confounders [6, 7] . Inpatients are exposed to C. difficile vegetative forms and spores, and we speculate that gastric acidity and its iatrogenic suppression have little impact on the natural course of infection with spores. Use of laxatives was also not associated with CDAD in multivariate analysis. Thus, a reduction in the use of PPIs and laxatives, although perhaps advisable for other reasons, would not be expected to impact on the incidence of CDAD.
Fluoroquinolones were the class of antimicrobials most prone to induce CDAD. This represents a major change in the epidemiology of hospital-acquired CDAD, which is historically associated with use of cephalosporins and clindamycin [9, 13, [24] [25] [26] [27] [28] . Almost one-fourth of inpatients received fluoroquinolones, and it can be calculated that their population-attributable fraction of CDAD was 35.9%. This finding goes a long way in explaining the explosive spread of C. difficile in Quebec hospitals in [2003] [2004] : the introduction of a novel strainwhich, at the same time, caused more-severe diarrhea (and enhanced transmission by incontinent patients) and was highly resistant to quinolones-in an environment of massive use of fluoroquinolones among elderly patients must have created a vicious circle further compounded by frequent postmetronidazole relapses. Several other classes of antimicrobials (all 3 generations of cephalosporins, macrolides, clindamycin, and b-lactam/b-lactamase inhibitors) were independently associated with CDAD with lower (and very similar) AHRs, constituting an intermediate-risk category. Their population-attributable fraction varied according to frequency of use from 10.7% for second-generation cephalosporins to as little as 1.5% for clindamycin. These findings differ somewhat from those of our previous study [4] , in which the risk associated with various classes of antimicrobials was assessed by a different method (number of patients who had received a given antibiotic divided by number of patient-days of use), which corresponded to a univariate analysis, with no adjustment for major confounders, such as age, duration of hospital stay, or the administration of other antibiotics.
Traditional infection-control measures have limited efficacy in reducing nosocomial transmission of C. difficile, the spores of which can survive for months in the hospital environment [19, 29] . Shortening the duration of hospitalization (by facilitating the transition from hospital care to home-based care in elderly patients) would reduce exposure, but this might have little impact, because the risk of CDAD did not increase linearly with longer durations of hospitalization, perhaps because a selection process occurs. Ultimately, control of nosocomial CDAD depends primarily on more judicious use of antimicrobial agents: sparing use of fluoroquinolones, substitution of intermediate-risk antibiotics with aminoglycosides when feasible (for instance in patients with intra-abdominal infections or pyelonephritis who have a normal renal function), and administration of trimethoprim-sulfamethoxazole to patients with urinary tract infections caused by a susceptible pathogen. For patients with community-acquired pneumonia requiring hospital admission, the risk of CDAD associated with a combination of ceftriaxone and azithromycin (the product of their AHRs is 2.57) is identical to that of levofloxacin (AHR, 2.52); the risk could be reduced by obtaining appropriate specimens and rapidly narrowing the spectrum, rather than relying on syndromic management. Duration of antimicrobial therapy is based more on tradition than evidence. For the first time, we were able to document that, for some antibiotics, the risk of CDAD was influenced by duration of use. Shorter courses of antibiotic therapy should be considered-for instance, for patients with pneumonia or intra-abdominal infections [30, 31] .
A limitation of our study is that its findings are relevant mostly to hospitals where this novel, hypervirulent, quinoloneresistant strain of C. difficile has emerged. However, this strain has been found in at least 6 US states [32] , and a recent report from Pittsburgh, Pennsylvania, described a large outbreak of CDAD related mostly to fluoroquinolones (with an etiologic fraction similar to ours), and a high proportion of patients needed a colectomy [33] . Other reports from the United States and Canada linking use of fluoroquinolones with CDAD [21, [34] [35] [36] [37] [38] and from Europe, where resistance to moxifloxacin has emerged [39, 40] , suggest that, although not necessarily caused by the same strain, fluoroquinolone-induced CDAD is widespread.
In conclusion, fluoroquinolones were the most important risk factor for CDAD during a large epidemic caused by a hypervirulent strain of C. difficile. Control of CDAD requires a reduction in the use of fluoroquinolones and of intermediaterisk antibiotics and shorter durations of therapy for common infections. Fluoroquinolones have become the most widely prescribed class of antibacterials in the United States [41] . Future guidelines for the use of antimicrobial agents need to take into consideration the risk of inducing CDAD.
